CollPlant Biotechnologies Ltd Funding: $4M Raised (Form D)

Keep reading

More on the people and the money behind CollPlant Biotechnologies Ltd, from the filings we hold.

More raises like this

Other Health Care raises filed within 90 days of this one, largest first.

Imperative Care, Inc. $100M, Mar 2026
Concept Medical, Inc. $60M, Apr 2026
Fourth Edge LLC $60M, Dec 2025
Route 92 Medical, Inc. $50M, Apr 2026
Neurotrigger Ltd. $725K, Dec 2025

What do you want to do with CollPlant Biotechnologies Ltd?

What the filing says

Offered: $4,000,000. Sold: $4,000,000. Left to sell: nothing, all of it is sold. (filing)
Investors: 8 had already invested. (filing)
Date of first sale: February 4, 2026. (filing)
Types of securities: Equity; Options, warrants or other rights to acquire another security; Securities to be acquired on exercise of an option, warrant or other right; Other: Series A warrants and series B warrants to purchase ordinary shares, including underlying ordinary shares upon exercise.. (filing)
Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters (marked as an estimate). It adds: “The Company intends to use the net proceeds for general corporate purposes, which may include but are not limited to, working capital and funding research and development programs.” (filing)
On the amounts offered and sold: the filing adds “Offering of unregistered series A warrants to purchase 1,600,000 ordinary shares, and unregistered series B warrants to purchase 1,600,000 ordinary shares. The total offering amount does not reflect warrants issued to placement agent (see Item 15).” (filing)
On sales commissions and finders' fees: the filing adds “H.C. Wainwright is entitled to 7.0% of gross proceeds cash fee, 1.0% of gross proceeds management fee, $35,000 non-accountable expenses, $15,950 clearing fees and warrants to purchase 96,000 ordinary shares at $1.5625/share for 5 years. This is estimated.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on CollPlant Biotechnologies Ltd See pricing

Filing history · 4 filings on this registrant

Each marker is one filing. The larger marker is the filing this page is about.

Other Health Care · by week

Trailing twelve months. 868 filings in Other Health Care, totalled by week. The dot is this raise, $4M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Company officers on record

Yehiel Tal

Chief Executive Officer and Interim Chairman of the Board of Directors

On the filing as: Executive Officer, Director.

Rehovot, ISRAEL

Yehiel Tal is named as Chief Executive Officer and Interim Chairman of the Board of Directors on the Form D that CollPlant Biotechnologies Ltd filed with the SEC on 17 February 2026, one of 12 people that filing names.

Eran Rotem

Deputy Chief Executive Officer and Chief Financial Officer